Assessment of Energetic Resonance by Cutaneous Stimulation on Withdrawal Alcohol Symptoms. (RESC)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Lyon, France
- Hopital croix rousse
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women between 18 and 80 years,
- Patient with alcohol addiction,
- Patient needing alcohol withdrawal in a hospital.
- Patient with social Security,
- Patient with inform consent signed.
Exclusion Criteria:
- Pregnant women
- Minor.
- Major with guardianship.
- People without sufficient information because of troubles of cognitive functions, or without sufficient knowledge of French language.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: Control
|
|
|
Experimental: Energetic Resonance by Cutaneous Stimulation
Energetic Resonance by Cutaneous Stimulation session in addition to standard treatment for patients with withdrawal alcohol symptoms.
|
Energetic Resonance by Cutaneous Stimulation (RESC) is a non-invasive method based on energetic Chinese medicine principles and digital contact.
RESC is characterized by echo phenomena between two stimulation points.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cushman Score measure after Energetic Resonance by Cutaneous Stimulation
Time Frame: daily during one week
|
CUSHMAN score is represented by a scale with 7 variables collecting physiological modifications or behavioural manifestations related to adrenergic answer, neurovegetative signs, confusion, nervousness, perceptive or hallucinatory phenomena.
|
daily during one week
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Anxiety depression scale
Time Frame: pre-screening, day 3 and day 7
|
pre-screening, day 3 and day 7
|
|
prescribed benzodiazepine amount
Time Frame: day 0 to day 7
|
day 0 to day 7
|
|
Analogic Visual Scale
Time Frame: before and after each Energetic Resonance by Cutaneous Stimulationsession at day 2, day 4 and day 6.
|
before and after each Energetic Resonance by Cutaneous Stimulationsession at day 2, day 4 and day 6.
|
|
Quality of life scale
Time Frame: day 0
|
day 0
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Claude Augustin-Normand, Dr, Hospices Civils de Lyon
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2013-840
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.